Press Releases
Agena Bioscience Announces EUA for High-Throughput, Low-Cost SARS-CoV-2 Panel
Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, announced the launch of the iPLEX® Pro SARS-CoV-2 Panel for qualitative detection of the novel coronavirus that causes COVID-19. Clinical laboratories can process more than 6000...
Press Releases
Sanofi invests in vaccine research and production
Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks. Aligned with its corporate strategy presented last December, Sanofi will...
Press Releases
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
IDEAYA Biosciences, Inc. and GlaxoSmithKline plc announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology.
The strategic partnership includes IDEAYA’s Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials...
Press Releases
Pfizer Announced FDA Approval of Oncology Supportive Care Biosimilar, NYVEPRIA
Pfizer Inc. announced the US FDA has approved NYVEPRIA, a biosimilar to Neulasta NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...
Press Releases
Sunovion Announces Health Canada Approval of KYNMOBI Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes
Sunovion Pharmaceuticals Inc. announced that Health Canada has approved KYNMOBI soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re-emergence or worsening of PD symptoms otherwise controlled with...
Press Releases
AstraZeneca to Supply Europe with 400M Doses of COVID-19 Vaccine
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end...
Drug Research
Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate
Catalent, Inc. , the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















